Culver City, United States
Indi Molecular is an emerging force in the Biotechnology and Health Care sectors, focusing on the development of synthetic molecules that mimic antibody properties. With a strategy centered around its unique protein catalyzed capture (PCC) technology, the company aims to revolutionize therapeutic and diagnostic processes. PCCs serve dual purposes as precision in vivo PET diagnostics and targeted therapeutics, notably in radiotherapy and chemotherapy.
Founded in 2013, Indi Molecular secured initial financial momentum with a $1.8 million seed round, subsequently followed by a substantial $11.5 million Series A in 2017. This investment round was backed by prominent investors including Asset Management Ventures, M Ventures, Legend Capital, and SABEY. Headquartered in the United States, the company is strategically positioned to address critical gaps in current therapeutic methodologies with its innovative PCC technology.
